Uncategorized

Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report

Published

on

Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version